Skip to main content
. Author manuscript; available in PMC: 2024 Feb 28.
Published in final edited form as: Circulation. 2022 Nov 7;147(9):703–714. doi: 10.1161/CIRCULATIONAHA.122.062746

Figure 3. Sub-group Analyses of Statin Prescription Rates at 6 Months.

Figure 3.

Abbreviations: anti-HTN: antihypertensive; CAC: coronary artery calcium; LDL: low density lipoprotein; Rx: prescription.

This figure demonstrates results of the primary analysis, statin prescription rates at 6 months, stratified by key patient characteristics. For the ethnicity/race subgroup analysis, we first classified patients with Hispanic ethnicity. Among non-Hispanic patients, we made subgroups based on race. We excluded subgroups with fewer than 10 individuals across arms for confidentiality. There was no significant heterogeneity in the treatment effect across patient subgroups (Supplement Table S2). The statin prescription rate was 0% for patients in the usual care arm with LDL-C <100 mg/dL or with missing LDL-C. Testing for heterogeneity of treatment effect using continuous variables (for age, DL-CAC score, and time since last visit) are listed in Supplement Table S2.